Product Name :
[D-Lys3]-GHRP-6
Description:
IC50: 0.9 μM [D-Lys3]-GHRP-6 is an antagonist at the ghrelin receptor (GHS-R1a) and weakly binds to melanocortin receptors (Ki = 26-120 μM). In vitro: [D-Lysa]GHRP-6 used similar affinities to bind to all the four MC receptors, to which the structurally related Met-enkephalin and the functionally related GHuRH, together with LHRH and somatostatin-14 did not bind. This (the low affinity of the GH-releasing/enkephalin peptides) may indicate that they do not interact with the MC receptors at pharmacological concentrations. [DLys3] GHRP-6 only used slightly higher affinity than GHRP-6 to bind to the MC1 receptor. . Compared with GHRP-6, [D-Lys3]GHRP-6 has higher affinity for all the MC receptors, especially for the MC3 and MC4 receptors. Interestingly, [D-Lys 3] GHRP-6 binds to the MC1 receptor with only slightly higher affinity compared with GHRP-6, which may indicate that the basic hydrophilic residue in position 8 is not important for the MC 1 receptor (as the same as he other MC receptor subtypes) [1,2]. The peptidic GHS-receptor antagonist (D-Lys3)-GHRP-6 (10-4 M) antagonized ghrelin (10-7 M) weakly, showing a much weaker affinity (IC50, 0.9×10-6 M) to the GHS-receptor than ghrelin (IC50, 0.3×10-9 M). Ghrelin increased the electrical activity in 76% of all cells inhibited by leptin (n=17). These data reveal that ghrelin interacts with the leptin hypothalamic network in the arcuate nucleus. Leptin and ghrelin oppositely effect on neurons in the arcuate nucleus, which may serve as a neurophysiological correlate of the orexigenic and anorectic effects of them . In vivo: The administration of D-Lys3-GHRP-6 (an antagonist of GHS receptors) alone had no significantly influence on GH secretion. Oppositely, pretreatment with this antagonist efficiently inhibited the stimulatory effect of AMPA and NMDA on GH secretion. To confirm this contention, further experiments to evaluate different protocols (doses, times, additional GHS receptor antagonists) of administration of D-Lys3-GHRP-6 are carried out. Nevertheless, it is possible that ghrelin may only intervene in situations of hypo- or hypersecretion of GH but not involved in the control of basal GH secretion . Clinical trial: So far, no clinical study has been conducted.
CAS:
136054-22-3
Molecular Weight:
930.11
Formula:
C49H63N13O6
Chemical Name:
(Z,2R)-6-amino-N-[(1S)-1-[(Z)-[(1R)-1-[(Z)-[(1S)-5-amino-1-(C-hydroxycarbonimidoyl)pentyl]-C-hydroxycarbonimidoyl]-2-phenylethyl]-C-hydroxycarbonimidoyl]-2-(1H-indol-3-yl)ethyl]-2-[(Z)-[(2R)-2-[(Z)-[(2S)-2-amino-1-hydroxy-3-(1H-imidazol-5-yl)propylidene]amino]-1-hydroxy-3-(1H-indol-3-yl)propylidene]amino]hexanimidic acid
Smiles :
N[C@@H](CC1=CN=CN1)/C(/O)=N/[C@H](CC1=CNC2=CC=CC=C12)/C(/O)=N/[C@H](CCCCN)/C(/O)=N/[C@@H](CC1=CNC2=CC=CC=C12)/C(/O)=N/[C@H](CC1C=CC=CC=1)/C(/O)=N/[C@@H](CCCCN)C(=N)O
InChiKey:
MGSNWNLPMHXGDD-DFWOJPNQSA-N
InChi :
InChI=1S/C49H63N13O6/c50-20-10-8-18-39(44(53)63)58-47(66)41(22-30-12-2-1-3-13-30)61-49(68)43(24-32-27-56-38-17-7-5-15-35(32)38)62-46(65)40(19-9-11-21-51)59-48(67)42(23-31-26-55-37-16-6-4-14-34(31)37)60-45(64)36(52)25-33-28-54-29-57-33/h1-7,12-17,26-29,36,39-43,55-56H,8-11,18-25,50-52H2,(H2,53,63)(H,54,57)(H,58,66)(H,59,67)(H,60,64)(H,61,68)(H,62,65)/t36-,39-,40+,41+,42+,43-/m0/s1
Purity:
≥98% (or refer to the Certificate of Analysis)
Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition :
Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.{{Celecoxib} MedChemExpress|{Celecoxib} COX|{Celecoxib} Biological Activity|{Celecoxib} References|{Celecoxib} supplier|{Celecoxib} Autophagy}
Shelf Life:
≥12 months if stored properly.
Stock Solution Storage:
0 – 4 oC for 1 month or refer to the Certificate of Analysis.
Additional information:
IC50: 0.9 μM [D-Lys3]-GHRP-6 is an antagonist at the ghrelin receptor (GHS-R1a) and weakly binds to melanocortin receptors (Ki = 26-120 μM). In vitro: [D-Lysa]GHRP-6 used similar affinities to bind to all the four MC receptors, to which the structurally related Met-enkephalin and the functionally related GHuRH, together with LHRH and somatostatin-14 did not bind. This (the low affinity of the GH-releasing/enkephalin peptides) may indicate that they do not interact with the MC receptors at pharmacological concentrations. [DLys3] GHRP-6 only used slightly higher affinity than GHRP-6 to bind to the MC1 receptor. . Compared with GHRP-6, [D-Lys3]GHRP-6 has higher affinity for all the MC receptors, especially for the MC3 and MC4 receptors. Interestingly, [D-Lys 3] GHRP-6 binds to the MC1 receptor with only slightly higher affinity compared with GHRP-6, which may indicate that the basic hydrophilic residue in position 8 is not important for the MC 1 receptor (as the same as he other MC receptor subtypes) [1,2]. The peptidic GHS-receptor antagonist (D-Lys3)-GHRP-6 (10-4 M) antagonized ghrelin (10-7 M) weakly, showing a much weaker affinity (IC50, 0.9×10-6 M) to the GHS-receptor than ghrelin (IC50, 0.3×10-9 M). Ghrelin increased the electrical activity in 76% of all cells inhibited by leptin (n=17). These data reveal that ghrelin interacts with the leptin hypothalamic network in the arcuate nucleus. Leptin and ghrelin oppositely effect on neurons in the arcuate nucleus, which may serve as a neurophysiological correlate of the orexigenic and anorectic effects of them . In vivo: The administration of D-Lys3-GHRP-6 (an antagonist of GHS receptors) alone had no significantly influence on GH secretion. Oppositely, pretreatment with this antagonist efficiently inhibited the stimulatory effect of AMPA and NMDA on GH secretion. To confirm this contention, further experiments to evaluate different protocols (doses, times, additional GHS receptor antagonists) of administration of D-Lys3-GHRP-6 are carried out.{{Everolimus} medchemexpress|{Everolimus} PI3K/Akt/mTOR|{Everolimus} Protocol|{Everolimus} In Vitro|{Everolimus} custom synthesis|{Everolimus} Epigenetic Reader Domain} Nevertheless, it is possible that ghrelin may only intervene in situations of hypo- or hypersecretion of GH but not involved in the control of basal GH secretion .PMID:23833812 Clinical trial: So far, no clinical study has been conducted.|Product information|CAS Number: 136054-22-3|Molecular Weight: 930.11|Formula: C49H63N13O6|Chemical Name: (Z,2R)-6-amino-N-[(1S)-1-[(Z)-[(1R)-1-[(Z)-[(1S)-5-amino-1-(C-hydroxycarbonimidoyl)pentyl]-C-hydroxycarbonimidoyl]-2-phenylethyl]-C-hydroxycarbonimidoyl]-2-(1H-indol-3-yl)ethyl]-2-[(Z)-[(2R)-2-[(Z)-[(2S)-2-amino-1-hydroxy-3-(1H-imidazol-5-yl)propylidene]amino]-1-hydroxy-3-(1H-indol-3-yl)propylidene]amino]hexanimidic acid|Smiles: N[C@@H](CC1=CN=CN1)/C(/O)=N/[C@H](CC1=CNC2=CC=CC=C12)/C(/O)=N/[C@H](CCCCN)/C(/O)=N/[C@@H](CC1=CNC2=CC=CC=C12)/C(/O)=N/[C@H](CC1C=CC=CC=1)/C(/O)=N/[C@@H](CCCCN)C(=N)O|InChiKey: MGSNWNLPMHXGDD-DFWOJPNQSA-N|InChi: InChI=1S/C49H63N13O6/c50-20-10-8-18-39(44(53)63)58-47(66)41(22-30-12-2-1-3-13-30)61-49(68)43(24-32-27-56-38-17-7-5-15-35(32)38)62-46(65)40(19-9-11-21-51)59-48(67)42(23-31-26-55-37-16-6-4-14-34(31)37)60-45(64)36(52)25-33-28-54-29-57-33/h1-7,12-17,26-29,36,39-43,55-56H,8-11,18-25,50-52H2,(H2,53,63)(H,54,57)(H,58,66)(H,59,67)(H,60,64)(H,61,68)(H,62,65)/t36-,39-,40+,41+,42+,43-/m0/s1|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.|Shelf Life: ≥12 months if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined|HS Tariff Code: 382200|Products are for research use only. Not for human use.|
